조용균 (성균관대학교 의과대학, 강북삼성병원) | 한빛사논문 > 한빛사

한빛사논문

조회295

성균관대학교 의과대학, 강북삼성병원

CV File 64 kb

Clin. Gastroenterol. Hepatol., Available online 3 July 2021. https://doi.org/10.1016/j.cgh.2021.06.042 Liver Fibrosis in Asians With Metabolic Dysfunction–Associated Fatty Liver Disease

Won Sohn^∗,a,b, Heon-Ju Kwon^‡,a, Yoosoo Chang^§,||,¶, Seungho Ryu^§,||,¶, Yong Kyun Cho^∗,b

^∗Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
^‡Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
^§Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
^||Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
^¶Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
^aAuthors share co-first authorship.
^bCorresponding author.

Abstract

Background & aims: This study aimed to evaluate risk factors associated with liver fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD).

Methods: A cross-sectional study of 967 Korean patients with MAFLD involved a cohort from a health screening program during the years 2015-2018. The patients were classified into 4 MAFLD subgroups: group 1 (overweight). group 2 (obese), group 3 (lean/normal weight with metabolic abnormalities), and group 4 (diabetes). Liver fibrosis was assessed based on liver stiffness measurement (LSM) value using 2-dimensional real-time magnetic resonance elastography. We investigated differences in liver fibrosis according to MAFLD subgroup classification and determined the risk factors for significant fibrosis.

Results: The mean age was 50.8 years, and 869 (90 %) patients were male. The mean value of LSM in magnetic resonance elastography was 2.48 ± 0.47 kPa. Significant fibrosis (LSM ≥2.97 kPa) was observed in 66 (6.8 %) of 967 patients. The proportion of significant fibrosis in MAFLD group 1, group 2, group 3, and group 4 was 1.3 %, 5.5 %, 6.4 %, and 18.9 %, respectively (P < .001). Multivariable analysis indicated that the risk factors for significant fibrosis were serum ferritin ≥300 ng/mL (odds ratio [OR], 1.96; 95 % confidence interval [CI], 1.10-3.49; P = .023), Fibrosis-4 ≥1.3 (OR, 2.97; 95 % CI, 1.68-5.24; P < .001), homeostatic model assessment of insulin resistance ≥2.0 (OR, 2.60; 95 % CI, 1.25-5.43; P = .011), metabolic syndrome (OR, 2.53; 95 % CI, 1.31-4.88; P = .006), and MAFLD group 4 (OR, 6.93; 95 % CI, 1.96-24.51; P = .003). However, the etiology of liver disease was not statistically associated with liver fibrosis.

Conclusion: Liver fibrosis in patients with MAFLD varies according to subgroup classification based on diabetes, body mass index, and metabolic risk factors.

논문정보

형식Research article
게재일2021년 07월 (BRIC 등록일 2021-08-13)
연구진국내 연구진
분야 의약학 > 응용의학

댓글 작성 로그인

CV 열람하기

연락처 보기